{"groups":[{"description":"Dose Escalation with 5 dose levels based on the patients actual bodyweight\n\nCyclophosphamide: 300 mg/m\\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3\n\nFludarabine: 30 mg/m\\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3\n\nAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells: 0.3x10\\^6- 15.0x10\\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0","id":"FG000","title":"0.3 x 10^6 CAR-BCMA T-cells Infused"},{"description":"Dose Escalation with 5 dose levels based on the patients actual bodyweight\n\nCyclophosphamide: 300 mg/m\\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3\n\nFludarabine: 30 mg/m\\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3\n\nAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells: 0.3x10\\^6- 15.0x10\\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0","id":"FG001","title":"1 x 10^6 CAR-BCMA T-cells Infused"},{"description":"Dose Escalation with 5 dose levels based on the patients actual bodyweight\n\nCyclophosphamide: 300 mg/m\\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3\n\nFludarabine: 30 mg/m\\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3\n\nAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells: 0.3x10\\^6- 15.0x10\\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0","id":"FG002","title":"3 x 10^6 CAR-BCMA T-cells Infused"},{"description":"Dose Escalation with 5 dose levels based on the patients actual bodyweight\n\nCyclophosphamide: 300 mg/m\\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3\n\nFludarabine: 30 mg/m\\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3\n\nAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells: 0.3x10\\^6- 15.0x10\\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0","id":"FG003","title":"9 x 10^6 CAR-BCMA T-cells Infused"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"}],"type":"Patient became ineligible for treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Patient did not get CAR T-Cells"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"16"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}